MedTrace Logo

RDD1609 as a Treatment for Idiopathic Pruritus Ani

NCT03757403 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-11-03

No results posted yet for this study

Summary

This is a double-blind, randomized, placebo-controlled, crossover trial, to test the hypothesis that RDD1609 is effective in treating idiopathic pruritus ani.

Conditions

  • Idiopathic Pruritus Ani

Interventions

DRUG

RDD1609

RDD1609 to be applied on the perianal area BID

DRUG

Mebendazole 100 MG

Mebendazole 100 mg single dose (single prophylactic dose of the anthelmintic medicine)

Sponsors & Collaborators

  • RDD Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Nir Barak, MD · RDD Pharma Ltd

  • Jeanette Melrose, MD · THE ATHERSTONE SURGERY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03757403 on ClinicalTrials.gov